Mangoceuticals, Inc., a pharmaceutical company based in Dallas, Texas, has formally requested the withdrawal of its Post-Effective Amendment No. 1 to the Registration Statement on Form S-1, initially filed with the U.S. Securities and Exchange Commission (SEC). The request, dated August 30, 2024, and submitted via EDGAR, was made under Rule 477 of the Securities Act of 1933. The company has decided not to proceed with the deregistration of certain shares of common stock that were previously registered under the statement. This withdrawal request is specific to the Post-Effective Amendment and does not affect any other filings with the SEC under the same file number. Jacob D. Cohen, Chairman and Chief Executive Officer of Mangoceuticals, signed the withdrawal request.

Mangoceuticals, Inc., a pharmaceutical company based in Dallas, Texas, has formally requested the withdrawal of its Post-Effective Amendment No. 1 to the Registration Statement on Form S-1, initially filed with the U.S. Securities and Exchange Commission (SEC). The request, dated August 30, 2024, and submitted via EDGAR, was made under Rule 477 of the Securities Act of 1933. The company has decided not to proceed with the deregistration of certain shares of common stock that were previously registered under the statement. This withdrawal request is specific to the Post-Effective Amendment and does not affect any other filings with the SEC under the same file number. Jacob D. Cohen, Chairman and Chief Executive Officer of Mangoceuticals, signed the withdrawal request.